ABSTRACT
UNLABELLED: The aim of this study was to compare the diagnostic value of TruScreen with that of already approved in practice methods for detection of precancerous conditions of the cervix. This study reviewed 301 patients; for analysis were included 260 women aged from 16 to 69 years, mean 35.82 years. They were divided into three groups. RESULTS: After statistical analysis of the results we found sensitivity of conventional Pap smear, colposcopy and TruScreen respectively 67.44%, 96.55% and 53.85%, and specificity respectively 83.93%, 45.90% and 78.79%. CONCLUSION: TruScreen is a representative of real time methods for cervical screening. Our results are close to the obtained in other studies: medium value sensitivity and high specificity of the method, which shows that there is a possibility for its use as a primary screening, and also in addition to cytology. TruScreen is especially suitable in places where no cytology laboratories and specialists are available. It is a quick method (result at the moment), does not require special qualification and long training of the operator (as opposed to colposcopy) and is well received by women. Sufficient number of cases remains to be collected for more accurate assessment of the potential of TruScreen. It is appropriate to identify if TruScreen has different diagnostic value in mild and severe cervical changes, and also its efficacy as a primary screening method and in combination with other already approved in practice screening methods.
